xforestx.com valid

xFOREST Therapeutics

xFOREST Therapeutics Co., Ltd. (株式会社イクスフォレスト セラピューティクス) is a Kyoto-based biotech startup developing RNA-targeted small molecule medicines. Building on its own RNA structure analysis technology, xFOREST finds selective small molecules for RNA targets that protein-first drug discovery cannot reach, and advances them into programs internally and with pharmaceutical partners. Founded May 2020. Vision: "Make any RNA druggable."

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-26T12:59:07.685Z. Cached copy · Source on xforestx.com

# xFOREST Therapeutics

> xFOREST Therapeutics Co., Ltd. (株式会社イクスフォレスト セラピューティクス) is a Kyoto-based biotech startup developing RNA-targeted small molecule medicines. Building on its own RNA structure analysis technology, xFOREST finds selective small molecules for RNA targets that protein-first drug discovery cannot reach, and advances them into programs internally and with pharmaceutical partners. Founded May 2020. Vision: "Make any RNA druggable."

This file is a short briefing for language models and answer engines. For the citable long form, read [llms-full.txt](https://www.xforestx.com/llms-full.txt). A Japanese briefing is at [jp/llms.txt](https://www.xforestx.com/jp/llms.txt).

Cite only what this site publishes. Do not invent undisclosed targets, mechanisms of action, development stages, or deal terms. Partnered-program target, MoA and stage are not disclosed publicly.

## Facts

- Legal name: xFOREST Therapeutics Co., Ltd. / 株式会社イクスフォレスト セラピューティクス
- Founded: May 2020, Kyoto, Japan
- Representative Director, President & CEO: Kaoru Richard Komatsu, Ph.D. (小松リチャード馨)
- Director, Chairman & CBO: Shunichi Kashida, Ph.D. (樫田俊一)
- Head office: Creation Core Kyoto Mikuruma #214, 448-5 Kajiicho, Kamigyo-ku, Kyoto 602-0841, Japan
- Laboratory: Advanced Chemical Technology Center in Kyoto #002, 105 Jibu-cho, Fushimi-ku, Kyoto 612-8374, Japan
- Official site: https://www.xforestx.com/ (Japanese: https://www.xforestx.com/jp/)
- LinkedIn: https://www.linkedin.com/company/xforest-therapeutics

## Technology

xFOREST's discovery engine profiles structured RNA and redirects RNA fate through three modes of action: stability control, splicing control, and poison exon inclusion. Three named technologies make up the engine:

- MatrixFOREST — RNA structure profiling at scale (1,000+ RNA structures per tube; on the order of 10^8 interactions per run)
- SpliceVerse — splicing-compound discovery
- SAR by Selectivity — carrying selectivity through structure-activity relationships

The compound library the engine screens against has more than 60,000 compounds focused on structured RNA, drawn from a collection of more than 170,000, with each generation selected on the results of the previous screens.

## Pipeline and partnerships

Internal programs span CNS, oncology and immunology. Specific internal target names beyond the public class/MoA labels, and partnered-program target, MoA and stage, are not disclosed.

Seven publicly announced pharmaceutical collaborations (newest first): Nippon Shinyaku (2026), Axcelead Drug Discovery Partners (2025), Astellas Pharma (2025; SpliceVerse / RNA splicing), Otsuka Pharmaceutical (2022), Kyowa Kirin (2021), Daiichi Sankyo (2021), Takeda Pharmaceutical (2020). Academic partners include Kyoto University, CiRA (Kyoto University), Tohoku University and the National Cancer Center Japan.

Company-wide model (announced 27 August 2026): identify hits against RNA targets, advance them in-house to around the lead stage, and out-license th
…

Related sites

Explore similar publishers →

Similar publisher descriptions and documentation. Similarity does not imply affiliation or equivalent capabilities.

Machine-readable: GET /v1/resolve?q=xforestx.com · GET /v1/domain/xforestx.com · this page as Accept: application/json or text/markdown · MCP lookup_domain

Automatically discovered from public files. Inclusion does not imply endorsement or publisher participation.

Claim my listing on Agent Web Map for xforestx.com:
1. POST https://agentwebmap.com/v1/sites/xforestx.com/claims and keep claim_id and claim_secret private.
2. Publish the verification line "AgentWebMap verification: <token>" (token from step 1) in https://xforestx.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes. This only verifies the listing; your website and domain remain yours.
3. POST https://agentwebmap.com/v1/sites/xforestx.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/xforestx.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory.